Hackensack, NJ, June 03, 2024 – The John Theurer Cancer
Center at Hackensack University Medical Center announced today that
its physicians and researchers will present 16 abstracts on
treatment and diagnostic progress in many different areas of
oncology during the Annual Meeting of American Society of Clinical
Oncology (ASCO) in Chicago, IL from June 4-8.
"At the John Theurer Cancer Center, we're dedicated to providing
extraordinary cancer care to our patients, which includes
conducting high-quality cancer research and cutting-edge clinical
trials," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chairman
and Executive Administrative Director, the John Theurer Cancer
Center. "We're pleased to add to an important body of research at
this premier oncology conference."
Abstracts from the John Theurer Cancer Center research that are
scheduled to be presented include:
- Phase I study of combined vorinostat (V), lenalidomide (L), and
dexamethasone (D) in patients (pts) with relapsed or refractory
multiple myeloma (MM). (8031) (Poster Discussion Session) - Friday,
June 4 from 2:00 p.m. - 6:00 p.m. in E450a
- Phase II study of denileukindiftitox with CHOP chemotherapy in
newly-diagnosed PTCL: CONCEPT trial. (8045) (Poster Discussion
Session) - Friday, June 4 from 2:00 p.m. - 6:00 p.m. in E450a
- Response of relapsed/refractory diffuse large B-cell lymphoma
(DLBCL) with nongerminal center B-cell phenotype to lenalidomide
(L) alone or in combination with rituximab (R). (8038) (Poster
Discussion Session) - Friday, June 4 from 2:00 p.m. - 6:00 p.m. in
E450a
- The association between the Mantle Cell Lymphoma International
Prognostic Index (MIPI) and survival in patients treated with
rituximab-HCVAD (RHCVAD) alternating with
rituximab-methotrexate-AraC (R-MTX-AraC). (8092) (General Poster
Session) – Saturday, June 5 from 8:00 am – 12:00 p.m.
in S Hall A2
- Effect of front-line therapy with either high-dose therapy and
autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy
(R-Hypercvad) on outcome in mantle cell lymphoma (MCL). (8067)
(General Poster Session) – Saturday, June 5 from 8:00 am
– 12:00 p.m. in S Hall A2
- Impact of high-risk classification by FISH on overall survival
in myeloma: An Eastern Cooperative Oncology Group (ECOG) study
E4A03. (10546) (General Poster Session) – Saturday, June 5
from 8:00 am – 12:00 p.m. in S Hall A2
- Interim results of phase II trial of pegylated liposomal
doxorubicin (PLD) followed by bexarotene in advanced cutaneous
T-cell lymphoma (CTCL). (8053) (General Poster Session) –
Saturday, June 5 from 8:00 am – 12:00 p.m. in S Hall A2
- Neurotoxic and peripheral neuropathic effects in preclinical
and clinical studies of carfilzomib (CFZ), a novel proteasome
inhibitor (PI). (8135) (General Poster Session) – Saturday,
June 5 from 8:00 am – 12:00 p.m. in S Hall A2
- Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND)
for patients with relapsed indolent B-cell lymphoma (RIL). (8078)
(General Poster Session) – Saturday, June 5 from 8:00 am
– 12:00 p.m. in S Hall A2
- Treatment patterns and outcome among patients with multiple
myeloma relapsing and or refractory to bortezomib and
immunomodulatory drugs: A multicenter International Myeloma Working
Group study. (8125) (General Poster Session) – Saturday, June
5 from 8:00 am – 12:00 p.m. in S Hall A2
- Update on vantage program to assess combined vorinostat (V) and
bortezomib (B) in patients (pts) with relapsed and/or refractory
(RR) multiple myeloma (MM). (8133) (General Poster Session) –
Saturday, June 5 from 8:00 am – 12:00 p.m. in S Hall A2
- Effect of early chemotherapy intensification with BEACOPP in
high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on
overall treatment outcome of ABVD. (8006) (Oral Abstract Session) -
Saturday, June 5 from 1:00 p.m. – 4:00 p.m. in E354a
- Elotuzumab in combination with bortezomib in patients with
relapsed/refractory multiple myeloma: A phase I study. (8003)
(Clinical Science Symposium) Saturday, June 5 from 4:30 p.m.
– 6:00 p.m. in E354a
- Phase Ib study of oral panobinostat (LBH589) plus intravenous
bortezomib in patients (Pts) with relapsed (Rel) or Rel and
refractory (Ref) multiple myeloma (MM). (8001) (Clinical Science
Symposium) Saturday, June 5 from 4:30 p.m. – 6:00 p.m. in
E354a
- Results of an ongoing open-label, phase II study of carfilzomib
in patients with relapsed and/or refractory multiple myeloma (R/R
MM). (8000) (Clinical Science Symposium) Saturday, June 5 from 4:30
p.m. – 6:00 p.m. in E354a
SOURCE